Response to Ruggles and Cheung,Re: “Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study”
Restricted accessReplyFirst published online October, 2024
Response to Ruggles and Cheung,Re: “Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study”
YaishI, GindisG, GreenmanY, et al.Sublingual estradiol offers no apparent advantage over combined oral estradiol and cyproterone acetate for gender-affirming hormone therapy of treatment-naive trans women: Results of a prospective pilot study. Transgend Health, 2023; 8(6):485–493; doi: 10.1089/trgh.2023.0022
2.
RugglesT, CheungAS. Re: “Sublingual estradiol offers no apparent advantage over combined oral estradiol and cyproterone acetate for gender-affirming hormone therapy of treatment-naive trans women: Results of a prospective pilot study”. Transgend Health, 2024; 9(5):459.
3.
Even ZoharN, SoferY, YaishI, et al.Low-dose cyproterone acetate treatment for transgender women. J Sex Med, 2021; 18(7):1292–1298; doi: 10.1016/j.jsxm.2021.04.008
4.
MillwardCP, KeshwaraSM, IslimAI, et al.Development and growth of intracranial meningiomas in transgender women taking cyproterone acetate as gender-affirming progestogen therapy: A systematic review. Transgend Health, 2022; 7(6):473–483; doi: 10.1089/trgh.2021.0025
5.
LeeKS, ZhangJJY, KirollosR, et al.A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep, 2022; 12(1):1942; doi: 10.1038/s41598-022-05773-z
6.
BessoneF, LucenaMI, RomaMG, et al.Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: Report of 22 cases. Liver Int, 2016; 36(2):302–310; doi: 10.1111/liv.12899
